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Backgrounds: Recently, we have considered two new ﬁndings in genetics of 21-hydroxylase deﬁciency with
great interested: the existence of rare RCCX trimodular haplotypes, where the CYP21A2 like-gene
downstream of the TNXA gene carries from one to six pseudogene mutations, and population speciﬁc allelic
frequencies of wild-type CYP21A2 loci in the CYP21A1P pseudogene. Both these events represent a further
complication in CYP21A2 genetics. Therefore, the choice of the molecular protocol becomes a crucial point
when genetic analysis is required. In this regard, we must consider that the literature is still lacking consistent
data on the Italian population. For this reason, we report genetic results obtained on 375 healthy individuals
of Italian origin.
Methods: Different genetic protocols were compared and novel molecular strategies were performed.
Results: In our group, only two known haplotypes were identiﬁed. In addition, speciﬁc allelic frequencies of
CYP21A2 wild-type loci in the pseudogene have been established.
Conclusions: Based on our results, we can afﬁrm that the employment of different molecular methods is
necessary to ensure a correct CYP21A2 genotyping. In order to avoid mistakes both in patient diagnosis and/or
in risk evaluation of the relatives, each case should be investigated in function of a careful clinical evaluation
and the molecular test should be performed in specialized centres.© 2013 The Authors. Published by Elsevier B.V. Open access under CC BY-NC-ND license. 1. Introduction
The gene encoding 21-hydroxylase, CYP21A2, is located in the HLA
class III region on the short arm of chromosome 6p21.3 [1]. In this
region, four tandemly arranged genes - serine/threonine Kinase RP,
complement C4, steroid 21-hydroxylase CYP21, and tenascin TNX – are
organized as a genetic unit designated as a RCCX module. In a RCCX
bimodular haplotype, duplication of the RCCX module occurs and
the orientation of genes, from telomere to centromere, is: RP1-C4A-
CYP21A1P-TNXA-RP2-C4B-CYP21A2-TNXB. The three pseudogenes,
CYP21A1P-TNXA and RP2, located between the two C4 loci, do not
encode functional proteins [2,3].
In the Caucasian population, bimodular and monomodular RCCX
organizations occur with frequencies of 69% and 17%, respectively,
while trimodular RCCX haplotypes have a frequency of about 14%
[4]. A trimodular haplotype carrying one copy of the CYP21A1P
pseudogene and two copies of the CYP21A2 gene has been described
in different nationalities [5–10]. In most cases, the CYP21A2 copy. Gemelli 8, 00168 Rome, Italy.
olino).
.V. Open access under CC BY-NC-ND licensedownstream of the TNXA gene showed a wild-type sequence or the
IVS-13A/C>G mutation while the CYP21A2 gene next to TNXB carried
the p.Q318X mutation [6–10].
Recently, we have read with great interest the papers by Tsai et al.
[5,11], where the authors report, as the ﬁrst ﬁnding, that, in the
Chinese population, the existence of a CYP21A2-like gene downstream
of the TNXA gene is more abundant than that of the duplicated
CYP21A2 gene. Four new haplotypes were reported [5]. Based on
their ﬁndings, the authors suggest speciﬁc ampliﬁcation protocols
for an accurate and faultless detection of CYP21A2 gene downstream
of the TNXB gene [5,11]. In fact, according to Tsai et al., both conventional
CYP21A2 ampliﬁcation protocols (a two-step PCR or an allele-speciﬁc
CYP21A2 PCR) and MLPA (Multiplex Ligation Probe Ampliﬁcation)
assay could lead to a misinterpretation of CYP21A2 genotyping because
these methods might “catch” both the CYP21A2-like and CYP21A2 gene
downstream of the TNXB gene [5,11].
A second ﬁnding regards the existence of CYP21A2 wild-type loci
in the CYP21A1P pseudogene [5,11]. Speciﬁc allelic frequencies of
these wild-type loci were reported in the studied population and
some differences with other literature data were underlined [11].
Since MLPA probes for CYP21A2 exons 3, 4, 6 and 8 contain the wild
type sequence for Del8bp, p.I172N, Cluster E6 and p.Q318Xmutations
respectively, we assume that, if these mutations are not present in the
pseudogene, MLPA probes also “catch” these wild-type loci which
might lead to a misinterpretation of MLPA results.. 
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deﬁciency, we consider the ﬁndings of Tsai et al. [5,11] very interesting,
because thesemay inﬂuence the choice of a diagnosticmolecular proto-
col. Unfortunately, we must consider that the literature is still lacking
consistent data on the Italian population regarding both the existence
of rare RCCX trimodular haplotypes and allelic frequencies of
wild-type CYP21A2 loci in the CYP21A1P pseudogene. For these
reasons, in the present study, we report results obtained from the
genetic study of 375 healthy individuals of Italian origin.
2. Material and methods
2.1. Subjects
392 unrelated, healthy individuals of Italian origin were recruited.
Written informed consent for genetic studywas obtained in compliance
with the Helsinki Declaration and was approved by the Catholic
University Ethics Committee (Reference Number: P6242008).
An EDTA blood sample was collected and genomic DNAwas isolated
using High Pure PCR Template Preparation Kits (Roche Diagnostic, USA).
2.2. Detection of the CYP21A2 gene downstream of the TNXA gene
The protocol proposed by Tsai et al. was performed and a 6.1 Kb PCR
product containing the entire CYP21A1P and partial TNXA genes wasFig. 1.Methods in genetic analysis. (A) Bimodular haplotype (RP1-C4A-CYP21A1P-TNXA-RP2-
and 8.5 Kb fragments ampliﬁcation. Solid horizontal arrows represent the location and direc
restriction pattern of 6.1 Kb fragment. In this case, 3207, 2315 and 591 bp fragments
CYP21A2-TNXA-RP2-C4B-CYP21A2-TNXB) carrying a CYP21A1P pseudogene and two copies o
CYP779f/XA-36 F for 6.1 Kb fragment ampliﬁcation. Bottom: TaqI restriction pattern of 6.1 K
for isolation of CYP21A2 gene downstream of the TNXA gene from 6.1 Kb PCR product. Tw
template. P3 and PROMR primers are speciﬁc for CYP21A2 gene, since they target the wild-ampliﬁed using CYP-779f (5′-aggtgggctgttttcctttca-3′, nt-799 to -779,
according Higashi et al. numeration [12]) and XA-36 F (5′-ggacccaga
aactccaggtgg-3′, nt 4252–4272, GenBank accession: S38953) primers
[5] (Fig. 1A).
500 ng of PCR product were used for enzymatic restriction with TaqI
and, after incubation at 65 °C for 2 h, the completely digested PCR prod-
uctswere analyzed by electrophoresis on a 1.0% agarose gel. In a common
RCCXbimodular condition, three fragments of 3207, 2315 and 591 bp are
obtained from the TaqI cleavage analysis of the 6.1-kb template (Fig. 1A).
On the contrary, when a CYP21A2 gene is present downstream of the
TNXA gene, the restriction pattern of the 6.1-Kb PCR amplicon shows
fragments of 3738, 3207, 2315, 591 and 60 bp (Fig. 1B).
2.3. Molecular characterization of identiﬁed CYP21A2 genes downstream
of the TNXA gene
The identiﬁed 3738 bp fragment, that includes the whole sequence
of the CYP21A2 gene downstream of the TNXA gene [being generated
by the Taq I cutting at −740 and 2995 positions according to Higashi
et al. numeration [12]] was subsequently isolated from agarose gel
(QIAEX II Gel Extraction Kit, Qiagen, Hilden, Germany) and sequenced
using internal primers (available on request).
Results obtained by this protocol were then conﬁrmed using a
second strategy developed in our laboratory (Fig. 1C): the 6.1 Kb tem-
plate was sequenced using the non-speciﬁc 2R primer [5′-caccttcggagaC4B-CYP21A2-TNXB) of RCCX region on chromosome 6p.21.3 and used strategies for 6.1
tion of primers CYP779f/XA-36 F (6.1 Kb) and CYP779f/Tena32F (8.5 Kb). Bottom: TaqI
have been obtained. (B) Trimodular haplotype (RP1-C4A-CYP21A1P-TNXA-RP2-C4B-
f CYP21A2 gene. Solid horizontal arrows represent the location and direction of primers
b fragment producing fragments of 3738, 3207, 2315, 591 and 60 bp. (C) Used strategy
o nested PCR, using primers CYP5/PROMR and P3/XA-36 F, were performed on 6.1 Kb
type sequence of exon 3 missing of the 8 bp deletion (present only in pseudogene).
Table 1
Allelic frequencies of CYP21A2 wild-type loci in CYP21A1P pseudogenes of 100 healthy
Italians individuals (200 chromosomes).
p.P30 p.V281 p.F306 p.Q318 p.R356
Homozygous individuals 2 16 0 6 38
Heterozygous individuals 2 22 1 20 38
Total wild-type chromosomes 6 54 1 32 114
Allelic frequency (%) 3 27 0.5 16 57
Note: no wild type positions were found for the others investigated loci (−126 (C),
-113 (G), -110 (T), -103 (A), IVS2-13A/C, 707-714GAGACTAC, p.I172, p.I236, p.V237
and p.M239).
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obtained sequence showed the CYP21A1P 8 bp exon 3 deletion in
heterozygous status, we assumed that this mutation was in the
pseudogene, while the wild-type sequence belonged to a CYP21A2 gene
downstream of the TNXA gene. Therefore, in order to isolate this
CYP21A2 gene downstream of the TNXA, we performed two nested PCR
on 6.1-Kb fragment using speciﬁc, previously described, CYP21A2
primers: CYP5/PROMR (fragment1) and P3/ XA36F (fragment 2) [13]
(Fig. 1C). P3 and PROMR primers are speciﬁc for the CYP21A2 gene,
since they target the wild-type sequence of exon 3 where the 8 bp
deletion maps (present only in the pseudogene). Sequence analysis of
both fragments was performed using internal primers. The results were
analysed using the SeqScape v2.5 software package (Applied Biosystems,
USA). The CYP21A2 sequence references were: NCBI-AL049547 and
NC-000006.
2.4. Analysis of the CYP21A2 gene downstream of the TNXB gene
In addition to our conventional ampliﬁcation protocol [14], a full
CYP21A2 gene (8.5 Kb PCR), containing the downstream sequence of
the TNXB gene, was ampliﬁed according to Lee et al. [15] (Fig. 1A).
Speciﬁc internal primers were used for CYP21A2 sequencing [14].
The results were analysed using the SeqScape v2.5 software package
(Applied Biosystems, USA). The CYP21A2 sequence references were:
NCBI-AL049547 and NC-000006.
2.5. MLPA analysis
MLPA analysis was performed as previously described [16,17].
2.6. Identiﬁcation of CYP21A2 wild-type loci in CYP21A1P pseudogene
The research of speciﬁc CYP21A2 wild-type loci (g.-126C, g.-113G,
g.-110 T, g.-103A, p.P30, IVS2-13A/C, 707-714GAGACTAC, p.I172,
p.I236, p.V237, p.M239, p.V281, p.F306, p.Q318, p.R356) within the
pseudogene was performed on 100 healthy individuals showing
fragments of 3207, 2315 and 591 bp after the TaqI cleavage analysis
of the 6.1-kb PCR product.
Direct sequencing of the 6.1-Kb undigested PCR template (internal
sequencing primers available on request) was performed. The results
were analysed using the SeqScape v2.5 software package (Applied
Biosystems, USA). The CYP21A1P sequence reference was: M13935.
3. Results
3.1. Detection of the CYP21A2 gene downstream of the TNXA gene in 392
healthy individuals
375 out of 392 DNA samples were successfully ampliﬁed giving a
6.1-Kb fragment. Following TaqI cleavage analysis of these 6.1-Kb
fragments, 18 PCR templates produced fragments of 3738, 3207,
2315, 591 and 60 bp. Therefore, 2.4% of studied chromosomes carried
a CYP21A2 gene downstream of the TNXA gene.
3.2. Molecular characterization of 18 identiﬁed CYP21A2 genes
downstream of the TNXA gene
Complete sequence of all CYP21A2 isolated geneswas performed. No
mutations were found and all 18 analyzed samples showed a wild-type
sequence.
3.3. Analysis of the CYP21A2 gene downstream of the TNXB gene
Sequencing analysis of the CYP21A2 gene downstream of the TNXB
gene was performed in all 18 identiﬁed individuals carrying a second
CYP21A2 gene downstream of the TNXA gene.Both ampliﬁcation protocols used showed identical sequencing
results: 14 individuals carried the p.Q318X in heterozygous status
while 4 resulted as wild-type. In all 14 cases, the p.Q318X mutation
was in linkage disequilibrium with two uncommon genetic variants:
a G > A substitution in intron 2 (IVS2-79G/A) and a C > T change at
nucleotide 13 in the 3′-untranslated region (UTR), conﬁrming the
same ancestry of this rare duplicate haplotype [9]. Sequences obtained
using our ampliﬁcation protocol showed that at the level of p.Q318X
mutation (CAG > TAG), the wild-type base peak (C) was twofold-
higher than the mutated (T) base peak. The same ﬁndings were found
on the remaining two SNPs in linkage with the p.Q318X mutation.
These results conﬁrm that our ampliﬁcation protocol of the CYP21A2
gene [14], differently to themethod of Tsai et al. [5], is also able to detect
the CYP21A2 gene downstream of the TNXA gene.
3.4. MLPA analysis
MLPA analysis was performed on all 18 identiﬁed individuals
carrying a CYP21A2 gene downstream of the TNXA gene. CYP21A2
duplication was conﬁrmed in all cases. However, the speciﬁc CYP21A2
probe for exon 8 showed a normal RPR (relative peak ratio) value
(range 0.7–1.3) for all 14 individuals carrying the p.Q318X mutation
on CYP21A2 gene downstream of the TNXB. RPR of all other CYP21A2
probes was >1.3.
3.5. Identiﬁcation of CYP21A2 wild-type loci in CYP21A1P pseudogene
Complete CYP21A1P pseudogene sequencing was performed on
100 healthy individuals who showed only the 3.2-Kb fragment, in
association with 2.3-Kb and 591 bp fragments, after 6.1-Kb PCR TaqI
digestion. One or more heterozygous positions were detected along
the sequence for all 100 analyzed samples. Consequently, 200
chromosomeswere studied. Allelic frequencies of wild-type investigated
loci are reported in Table 1.
Regarding the E6 Cluster mutation analysis, we identiﬁed the 238
aminoacid deletion in 8 individuals (7 heterozygous and 1 homozygous)
and the presence of a lysine (normally asparagines in CYP21A1P gene) at
position 236 in 11 individuals (8 heterozygous and 3 homozygous).
4. Discussion
Copy number variations (CNVs) have been described for the RCCX
locus: the presence of two RCCX modules is the standard, while one,
three or fourmodules are rare arrangements. The trimodular organization
accounts for only 14% of the chromosomes and the majority of these
carry two copies of the CYP21A1P pseudogene, and one copy of the
CYP21A2 gene [4]. However, a trimodular haplotype with two copies
of the CYP21A2 gene and one copy of the CYP21A1P pseudogene
has been also described [5–10]. In most cases, the CYP21A2 gene
downstream of the TNXA gene showed a wild-type sequence or the
IVS2-13A/C > G mutation while the CYP21A2 gene next to TNXB
carried the p.Q318X mutation [6–10]. No others trimodular haplotypes
associated with different CYP21A2 mutations were reported before
2011.
Fig. 2. Trimodular haplotypes in healthy Italian individuals. (A) Haplotype with two wild type copies of CYP21A2 gene. (B) Haplotype carrying a wild type CYP21A2 gene
downstream of the TNXA and a mutated (p.Q318X) CYP21A2 copy next to TNXB.
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of the CYP21A2 like-gene downstream of the TNXA gene carried from
one to six pseudogene mutations [5]. Based of their ﬁndings, authors
have therefore suggested speciﬁc ampliﬁcation protocols for a correct
CYP21A2 molecular diagnosis, afﬁrming that previously reported PCR
methods and MLPA assay might lead to a misinterpretation of
CYP21A2 genotyping [5,11].
However, the data published by Tsai et al. [5,11] regard mainly
the Chinese population (Taiwanese individuals), and no data are
available on the Italian population regarding the existence of similar
rare haplotypes. For this reason, here we report data obtained on
375 unrelated, healthy Italian individuals. In our group, 2.4% of
enrolled individuals carried a CYP21A2 gene downstream of the
TNXA. Only two well known haplotypes were identiﬁed: the ﬁrst
one with two CYP21A2 wild-type genes and the second carrying a
wild-type CYP21A2 gene downstream of the TNXA gene and a mutated
(p.Q318X) CYP21A2 gene next to TNXB (Fig. 2). These results were
obtained using both Tsai et al. ampliﬁcation protocols [5] and our
routine molecular methods [14,16].
Our haplotypes were previously described in different Caucasian
populations where the frequency of the CYP21A2 gene downstream of
the TNXA has been speciﬁcally reported bymeans different ofmolecular
methods [6–10]. Herewe showadditional data on the Italian population
and verify that, to date, the existence of rare trimodular haplotypes,
carrying a CYP21A2-like gene with multiple pseudogene mutations,
surprisingly results in a genetic event restricted to the Chinese population.
Regarding the existence of wild-type loci in the CYP21A1P
pseudogene, only two studies are, to date, present in the literature
[5,18]. Here, we report that in Italian population obtained frequencies
have been 3%, 27%,16% and 57% for p.P30, p.V281, p.Q318 and p.R356
position, respectively (Table 1). No more wild-type loci have been
detected. Our results showed some differences compared to other
literature data. In fact, while Canturk et al. [18] reported frequencies
of 0.3% and 3.6% for nt 707-714GAGACTAC and p.I172 wild-type
loci, our data agree with those by Tsai et al. who report a 0% frequency
for these wild-type loci [5]. However, in agreement with Canturk et al.
[18], we obtained a 3% frequency for p.P30 wild-type locus, although
Tsai et al. reported a frequency of 24% [5]. Furthermore, Tsai et al.
underlined that the wild-type p.P30 locus in the pseudogene is
always in linkage with p.L62, while p.L30 mutation co-segregates
with p.H62 in the gene sequence [11]. In this regard, however,
Canturk et al. report a wild-type locus p.P30 in the pseudogene in
association with p.H62 rather than p.L62 [18]. Tsai et al. considered
this ﬁnding by Canturk as a misinterpretation result between cis/trans
allele of the PCR product [11]. Interestingly, we identiﬁed two
homozygous individuals p.L30/p.L30, p.L62/p.L62 and a subject
homozygous for p.L30 allele and heterozygous at position 62
(p.L62/p.H62). For this reason, we can afﬁrm that there is not an
apparent linkage between p.P30 and p.L62 alleles in our population, and
that the resultsmay be strongly dependent on the population considered.
No wild type positions were detected within Cluster E6. However,
we identiﬁed the 238 aminoacid deletion in 9 chromosomes (4.5%)and, as recently reported [19], we conﬁrm that also this pseudogene
mutation can be transferred to active gene by micro conversion events.
Finally, the frequency of wild-type p.R356 locus was highest (57%)
among all studied loci. This observation is in agreement with both
Canturk et al. [18] and Tsai et al.’s [5] studies.
Considering the above results, and based on our experience, we
can assume that the interpretation of MLPA data cannot be severely
affected by the presence of these identiﬁed wild-type loci in the
pseudogene. The exon 8 probe remains the only probe that can
show an ambiguous RPA value due a probable presence of a
wild-type p.Q318 locus in the pseudogene. However, this is a well
know event that is routinely taken into account by expert workers
in this ﬁeld [16,17].
In this regard, we would like to stress that MLPA assay, when used
as ﬁrst level analysis, remains a simple, rapid, sensitive and high
throughput tool for molecular diagnosis of 21-hydroxylase deﬁciency,
allowing the simultaneous study of several samples in the same
experiment and the investigation both of the active gene and the
pseudogene in each patient [16]. In fact, if no CYP21A2 gene duplication
is detected by MLPA, an allele speciﬁc PCR protocol can be adequately
used as second analysis level [6–10,14]. On the contrary, when a
CYP21A2 duplication is identiﬁed, performing speciﬁc ampliﬁcation
protocols, as suggested by Tsai el al. [5], it allows an accurate detection
of mutations on the CYP21A2 gene next to TNXB. However, in a
trimodular condition, in order to isolate the CYP21A2 copy present
within the 6.1 Kb PCR product, speciﬁc strategies (similar to what we
have described here) must be used, since the exact sequence of this
copy must be unequivocally established. In fact, clinical observation of
all individuals carrying the p.Q318X mutation on the duplicated gene
and a second pathogenic mutation in trans on the third CYP21A2 allele,
shows that these individuals are clinically unaffected because they carry
a trimodular haplotype with a wild type functional CYP21A2 copy
downstream of the TNXA gene [20].
In conclusion, in order to ensure correct genotyping and to avoid
mistakes both in patient diagnosis and/or in the risk evaluation of the
in relatives, we can afﬁrm that the employment of different molecular
methods is necessary for molecular diagnosis of 21-hydroxyalse
deﬁciency. Although several ﬂowcharts have been suggested for this
purpose [5,21], we believe that it is difﬁcult to establish a universal
consensus protocol. In fact, each case should be investigated in function
of careful clinical evaluation and themolecular test should be performed
in specialized centres able to provide a complete result.References
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